A: During clinical trials
the most frequent
adverse events
resulting in
discontinuation of
Acomplia (Zimulti)
were depression,
anxiety, and nausea.
Despres JP, et al. Effects of
rimonabant on metabolic risk factors
in overweight patients with
dyslipidemia. N Engl J Med. 2005 Nov
17;353(20):2121-34.
the most frequent
adverse events
resulting in
discontinuation of
Acomplia (Zimulti)
were depression,
anxiety, and nausea.
Despres JP, et al. Effects of
rimonabant on metabolic risk factors
in overweight patients with
dyslipidemia. N Engl J Med. 2005 Nov
17;353(20):2121-34.
Promising Weight Loss Medication...
Now that a promising new prescription anti-obesity drug, rimonabant, is
actually available in the U.K., Germany and several other countries, the
launch of the most anticipated weight-loss medication since Fen-phen is
generating a great deal of excitement among millions of obese and seriously
overweight Americans and Europeans.
The drug, marketed in Europe as Acomplia, ultimately is expected to reach
the United States under the name Zimulti. Whatever the trade name,
rimonabant has been hailed by some doctors on the basis of clinical trials as
a major breakthrough in treating obesity.
Zimulti is Acomplia...
Sanofi-Aventis, developer of rimonabant which is now sold in a number of
European countries, Argentina and Mexico as Acomplia, has long been coy
about what name it intends to use if the FDA approves the diet drug for U.S.
sale.
But the pros-and-cons of rimonabant are cheduled to be aired by an FDA
advisory panel on June 13th, and the official notice of the hearing published
in the Federal Register says the panel will discuss "the efficacy and safety of
new drug application (NDA) 21-888, proposed tradename Zimulti
(rimonabant)."
Rimonabant Reduces Appetite...
Rimonabant (SR141716) is an anorectic anti-obesity drug. It is a CB1
cannabinoid receptor antagonist. Its main avenue of effect is reduction in
appetite. Rimonabant is currently being sold in the United Kingdom by
Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name
Acomplia. It is believed, although not confirmed, that if the drug is approved in
the United States, it will be sold under the trade name Zimulti.
Rimonabant Multi-Use Drug...
An experimental wonder drug, Rimonabant, helps you lose weight, quit
smoking and it also helps protect your heart. Trials have shown that 33% of
people on Rimonabant lost 10% of body weight and kept their weight down for
two years - this is a record, no other diet drug has managed to keep a
person's weight down for so long.
The second 33% lost 5% of body weight and kept it down.
Now that a promising new prescription anti-obesity drug, rimonabant, is
actually available in the U.K., Germany and several other countries, the
launch of the most anticipated weight-loss medication since Fen-phen is
generating a great deal of excitement among millions of obese and seriously
overweight Americans and Europeans.
The drug, marketed in Europe as Acomplia, ultimately is expected to reach
the United States under the name Zimulti. Whatever the trade name,
rimonabant has been hailed by some doctors on the basis of clinical trials as
a major breakthrough in treating obesity.
Zimulti is Acomplia...
Sanofi-Aventis, developer of rimonabant which is now sold in a number of
European countries, Argentina and Mexico as Acomplia, has long been coy
about what name it intends to use if the FDA approves the diet drug for U.S.
sale.
But the pros-and-cons of rimonabant are cheduled to be aired by an FDA
advisory panel on June 13th, and the official notice of the hearing published
in the Federal Register says the panel will discuss "the efficacy and safety of
new drug application (NDA) 21-888, proposed tradename Zimulti
(rimonabant)."
Rimonabant Reduces Appetite...
Rimonabant (SR141716) is an anorectic anti-obesity drug. It is a CB1
cannabinoid receptor antagonist. Its main avenue of effect is reduction in
appetite. Rimonabant is currently being sold in the United Kingdom by
Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name
Acomplia. It is believed, although not confirmed, that if the drug is approved in
the United States, it will be sold under the trade name Zimulti.
Rimonabant Multi-Use Drug...
An experimental wonder drug, Rimonabant, helps you lose weight, quit
smoking and it also helps protect your heart. Trials have shown that 33% of
people on Rimonabant lost 10% of body weight and kept their weight down for
two years - this is a record, no other diet drug has managed to keep a
person's weight down for so long.
The second 33% lost 5% of body weight and kept it down.
This publications contains the opinions and ideas of its author(s). It is intended to provide helpful and informative material
on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering
medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other
competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for
any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and
application of any of the contents of this site.
on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering
medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other
competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for
any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and
application of any of the contents of this site.